Since 2018, the ADA Standards of Medical Care has provided evidence-based treatment guidelines for clinically suspected youth-onset T2D. We hypothesized adherence of pediatric diabetes providers to these guidelines was poor. We conducted a retrospective chart review of new onset T2D youth seen for initial consultation at our multidisciplinary tertiary care pediatric diabetes clinic. Between 7/20 and 6/2020, 90 youth completed initial visits: mean initial HbA1c 9.7% (6.5-14%) , mean age of 14.5 (range 9-19) , 57% female, 85% English-speaking, 60% Black, 10% Non-Hispanic White, and 27% Hispanic. Forty-one had an initial HbA1c <8.5% without acidosis, with 34 of these 41 (83%) started on metformin, in accordance with ADA guidelines. Four of the 41 (10%) patients were started on insulin therapy; these 4 had higher HbA1c than those started on metformin alone (8.1% vs. 6.7%, p = 0.0003) . In contrast, 49 of the 90 patients presented with an initial HbA1c ≥8.5% without acidosis. Of these 49, 6 (12%) were started on metformin and basal insulin, in accordance with ADA guidelines; however, the basal insulin was dosed at a mean of 0.27 unit/kg (0.20-0.45) rather than the recommended 0.5 unit/kg. Metformin with basal + prandial insulin was started in 23 (47%) . Sixteen of 49 (33%) were started on basal (0.20 unit/kg) + prandial insulin without metformin. Notably, in patients with HbA1c ≥8.5%, initial treatment choice did not differ by age, HbA1c, or race/ethnicity. Overall, providers exhibited greater fidelity to ADA treatment recommendations in those with HbA1c < 8.5% (83% adherence) than those with HbA1c ≥ 8.5% (12%) . In 80% of patients with a HbA1c ≥ 8.5, providers appeared to default to typical T1D treatment with an initial basal dose of 0.2 unit/kg and inclusion of prandial insulin. These findings demonstrate poor adherence to youth-onset T2D guidelines. A quality improvement project is underway to reduce practice variance and optimize the care of youth with newly diagnosed T2D.


J.H.Said: None. P.Wolfgram: n/a. S.M.Cabrera: None.


American Diabetes Association (1-18-ICTS-094)

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at